$RLFTF (related) Interesting post from Oct 2020 by Paul W. on FaceBK
NIH commissioned a F1000 Faculty review which was submitted on or around Sept 5th 2019 with a publication of September 12th 2019.
They wanted to study the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.
Now, we know that NIH reached out to Relief about RLF-100, it makes sense coming off the cusp of very fresh and recent studies (at that time).
There is NO doubt our Government knows they are into something (we know this) And this review has most probably been reviewed by many of you and further supports the hypothesis that:
1) VIP is a powerful peptide that can be used for multiple treatments
2) it’s on the radar of MANY as a viable therapeutic for a multitude of diseases
3) with the recent discoveries, renewed focus on testing we are just getting started
4) the government has already started studying / reviewing VIP as supported here as well as continued studies around things like influenza (currently in progress) ...and we are a part of it Bottom line, every piece of literature, every review, there is nothing but promise for this drug.
Here are a few excerpts to digest. The article itself is a additional reading material for those still compiling DD
---
Therefore, the immunomodulatory actions of VIP expand its abilities to treat acute and chronic inflammatory and autoimmune diseases, including sepsis 93, multiple sclerosis 94, Crohn’s disease 95, and type 1 diabetes 96.
<< VIP/PACAP and diabetes>>
Therefore, VPAC2 agonists and PAC1 agonists are candidates for the therapy of type 2 diabetes.
<< VIP/PACAP and cancers>>
Therefore, VPAC1 can be a target for anti-cancer drugs, since VPAC1 antagonists inhibit the growth of colonic cancer cell lines in vitro
<< Therapeutic potential of VIP>>
VIP has been suggested to be a therapeutic target for diseases such as diarrhea 58, IBD 95, diabetes 28, autoimmune diseases 115, neurodegenerative disorders 116, lung disease 117, 118, sarcoidosis 119, and cancers.
Finally, VIP-tagged nanoparticles may be a useful strategy for selective drug delivery to VPAC-overexpressing tumor cells and immune cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...BSU86ln-Jo
NIH commissioned a F1000 Faculty review which was submitted on or around Sept 5th 2019 with a publication of September 12th 2019.
They wanted to study the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.
Now, we know that NIH reached out to Relief about RLF-100, it makes sense coming off the cusp of very fresh and recent studies (at that time).
There is NO doubt our Government knows they are into something (we know this) And this review has most probably been reviewed by many of you and further supports the hypothesis that:
1) VIP is a powerful peptide that can be used for multiple treatments
2) it’s on the radar of MANY as a viable therapeutic for a multitude of diseases
3) with the recent discoveries, renewed focus on testing we are just getting started
4) the government has already started studying / reviewing VIP as supported here as well as continued studies around things like influenza (currently in progress) ...and we are a part of it Bottom line, every piece of literature, every review, there is nothing but promise for this drug.
Here are a few excerpts to digest. The article itself is a additional reading material for those still compiling DD
---
Therefore, the immunomodulatory actions of VIP expand its abilities to treat acute and chronic inflammatory and autoimmune diseases, including sepsis 93, multiple sclerosis 94, Crohn’s disease 95, and type 1 diabetes 96.
<< VIP/PACAP and diabetes>>
Therefore, VPAC2 agonists and PAC1 agonists are candidates for the therapy of type 2 diabetes.
<< VIP/PACAP and cancers>>
Therefore, VPAC1 can be a target for anti-cancer drugs, since VPAC1 antagonists inhibit the growth of colonic cancer cell lines in vitro
<< Therapeutic potential of VIP>>
VIP has been suggested to be a therapeutic target for diseases such as diarrhea 58, IBD 95, diabetes 28, autoimmune diseases 115, neurodegenerative disorders 116, lung disease 117, 118, sarcoidosis 119, and cancers.
Finally, VIP-tagged nanoparticles may be a useful strategy for selective drug delivery to VPAC-overexpressing tumor cells and immune cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...BSU86ln-Jo
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
